fig6
Figure 6. The probable benefit of patients for immunotherapy in different m6A subtypes. (A) TIDE score, (B) T cell dysfunction score, (C) MSI, and (D) T cell exclusion score in different groups of m6A subtypes. The scores between the two groups were compared through the Wilcoxon tests. TIDE: Tumor Immune Dysfunction and Exclusion; MSI: microsatellite instability.
